Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
Ultrasound is routinely used to screen for HCC. However, its utility is limited by numerous factors, including patient body habitus, operator experience and certain liver conditions, all of which contribute to decreases in sensitivity.
In conjunction with prevention efforts, the introduction of screening examinations has resulted in a reduction of nearly 6 million cancer-related deaths since 1975.
Breast density is most often discussed within the context of cancer risk, but new research suggests that it also could be used as a marker of cardiometabolic health.
The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.
Ultrasound is routinely used to screen for HCC. However, its utility is limited by numerous factors, including patient body habitus, operator experience and certain liver conditions, all of which contribute to decreases in sensitivity.
In conjunction with prevention efforts, the introduction of screening examinations has resulted in a reduction of nearly 6 million cancer-related deaths since 1975.
Breast density is most often discussed within the context of cancer risk, but new research suggests that it also could be used as a marker of cardiometabolic health.
The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.
